Bevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu)

贝伐珠单抗生物类似药（北京赛升/北京绿竹）

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu)
Drug Alias NameBevacizumabum biosimilar (Beijing Science Sun/Beijing Lvzhu)贝伐株单抗生物类似药（北京赛升/北京绿竹）anti-VEGF MAb (Beijing Science Sun/Beijing Lvzhu)贝伐赛珠单抗生物类似药（北京赛升/北京绿竹）贝伐单抗生物类似药（北京赛升/北京绿竹） +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Science Sun Pharmaceutical Co LtdBeijing Lvzhu Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Yat-Sen UniversityBeijing Lvzhu Biological Technology Co LtdBeijing Science Sun Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG